Related by context. All words. (Click for frequent words.) 73 PSMA ADC 72 MAGE A3 ASCI 72 MGd 71 alvespimycin 71 ganetespib 71 ELACYT 71 axitinib 71 Phase Ib study 71 enzastaurin 70 HER2 positive metastatic breast 70 Aplidin 70 elotuzumab 70 Phase Ib II 70 pertuzumab 70 Panzem R NCD 70 HuLuc# 70 CIMZIA ™ 70 sorafenib Nexavar 70 oral ridaforolimus 70 docetaxel Taxotere R 70 HGS ETR1 70 docetaxel chemotherapy 69 bevacizumab Avastin ® 69 aflibercept 69 YONDELIS 69 ongoing Phase 1b 69 nab paclitaxel 69 temsirolimus 69 gemcitabine chemotherapy 69 mapatumumab 69 XmAb# 69 CR# vcMMAE 69 CBLC# 69 seliciclib 69 phase IIb clinical 69 Alocrest 69 pegylated liposomal doxorubicin 69 glufosfamide 69 neratinib 68 zanolimumab 68 Amrubicin 68 IMA# 68 bendamustine 68 CA4P 68 lintuzumab 68 evaluating tivozanib 68 HuMax EGFr 68 BAY #-# 68 Aflibercept 68 Fludara 68 custirsen 68 trastuzumab DM1 T DM1 68 metastatic HRPC 68 lenalidomide dexamethasone 68 AEG# 68 PRT# 68 metastatic RCC 68 velafermin 68 APOPTONE 68 paclitaxel Taxol ® 68 docetaxel Taxotere 68 Ceflatonin 68 CTAP# Capsules 68 cediranib 68 mRCC 68 ixabepilone 68 sunitinib malate 68 EndoTAGTM 1 68 Allovectin 7 ® 68 radiation sensitizer 68 trastuzumab Herceptin R 68 viral kinetics 68 lesinurad 67 INCB# [001] 67 iniparib 67 SAR# [004] 67 Targretin 67 Cloretazine ® 67 BRIM2 67 pomalidomide 67 huC# DM4 67 cilengitide 67 metastatic castration resistant 67 tanespimycin 67 riociguat 67 ENMD # 67 sapacitabine 67 teriflunomide 67 HGS ETR2 67 HGS# 67 PEG SN# 67 tesmilifene 67 sorafenib tablets 67 depsipeptide 67 HRPC 67 carboplatin paclitaxel 67 Azedra 67 INCB# [003] 67 mycophenolate mofetil 67 eprotirome 67 CoFactor 67 Xelox 67 TORISEL 67 neoadjuvant 67 PXD# 67 OncoVEX GM CSF 67 atacicept 67 TACI Ig 67 dacetuzumab 67 posaconazole 66 EGFr 66 BRAF inhibitor 66 valopicitabine 66 romidepsin 66 Vitaxin 66 adjuvant radiation 66 thymalfasin 66 forodesine 66 Phase Ib clinical 66 IMGN# 66 XELOX 66 EndoTAG TM -1 66 mertansine 66 Virulizin ® 66 zalutumumab 66 Imprime PGG 66 phase IIa clinical 66 Exherin TM 66 goserelin 66 erlotinib Tarceva ® 66 Phase 2a trial 66 gemcitabine Gemzar 66 Xanafide 66 decitabine 66 capecitabine Xeloda R 66 Cloretazine R VNP#M 66 antitumor activity 66 docetaxel Taxotere ® 66 standard chemotherapy regimen 66 CCX# 66 CIMZIA TM 66 metastatic CRC 66 Glufosfamide 66 receptor tyrosine kinase inhibitor 66 oral prodrug 66 ritonavir boosted 66 vorinostat 66 initiate Phase 1b 66 metastatic renal cell carcinoma 66 ularitide 66 NVA# 66 Cloretazine R 66 metaglidasen 66 antiangiogenic agents 66 infusional 5-FU/LV 66 postoperative chemotherapy 66 Tavocept 66 castrate resistant prostate cancer 66 relapsed multiple myeloma 66 phase IIb trial 66 pharmacodynamic properties 66 dose cohort 66 Tarceva TM 66 Telintra 66 galiximab 66 Enzastaurin 66 relapsed refractory multiple myeloma 66 calcineurin inhibitors 66 registrational trial 66 Fludara ® 66 sorafenib Nexavar ® 66 milatuzumab 66 ToGA 66 pain palliation 66 Elotuzumab 66 recurrent NSCLC 66 sunitinib 66 vidofludimus 65 CYC# 65 concurrent chemoradiation 65 gemcitabine 65 EGFR TKI 65 FOLFOX6 chemotherapy regimen 65 oral antiviral 65 PEP# [003] 65 Proxinium TM 65 CLORETAZINE TM VNP#M 65 olaparib 65 HCV RESPOND 2 65 PEG Interferon lambda 65 relapsed MM 65 assessing T DM1 65 aflibercept VEGF Trap 65 veltuzumab 65 cariprazine 65 imetelstat 65 CYT# potent vascular disrupting 65 prostate cancer AIPC 65 gemcitabine carboplatin 65 Viramidine 65 cytokine refractory 65 EFAPROXYN 65 EGFR HER2 65 NXL# 65 sunitinib Sutent 65 recurrent glioblastoma multiforme 65 PROSTVAC TM 65 REOLYSIN ® 65 sorafenib Nexavar R 65 lumiliximab 65 sipuleucel T 65 talabostat 65 oral deforolimus 65 telaprevir dosed 65 pegylated interferons 65 low dose cytarabine 65 cetuximab Erbitux R 65 VELCADE melphalan 65 Cloretazine 65 nucleoside analog 65 Asentar 65 proteasome inhibitor 65 pan HDAC inhibitor 65 elacytarabine 65 Ceplene/IL-2 65 Nexavar sorafenib 65 preclinically 65 IFN α 65 adecatumumab MT# 65 IFN beta 65 antitumor effect 65 dacarbazine 65 metastatic colorectal carcinoma 65 lintuzumab SGN 65 FOLFIRI chemotherapy 65 Allovectin 7 R 65 Genasense ® 65 rNAPc2 65 Bezielle 65 HCV SPRINT 65 thalidomide Thalomid 65 pegylated interferon alfa 2b 65 Phenoptin 65 oxaliplatin Eloxatin 65 fosbretabulin 65 TRISENOX 65 farletuzumab 65 Aplidin R 65 PDX pralatrexate 65 R sorafenib tablets 65 paclitaxel Taxol R 65 relapsed ovarian cancer 65 SCCHN 65 cisplatin gemcitabine 65 TELCYTA 65 ZACTIMA 65 KRAS status 65 ancrod 65 IRX 2 65 myelofibrosis polycythemia vera 65 gemcitabine Gemzar ® 65 HGS ETR1 mapatumumab 65 midstage clinical 65 bevacizumab Avastin R 65 liposomal formulation 64 chemoradiotherapy 64 telaprevir VX 64 virus HCV protease inhibitor 64 metastatic hormone refractory 64 gefitinib Iressa 64 ASA# 64 trastuzumab DM1 64 metastatic colorectal 64 alkylating agent 64 CD# antibody [001] 64 Panzem NCD 64 capecitabine Xeloda 64 interferon gamma 1b 64 Vaxfectin TM 64 PS# [001] 64 bosutinib 64 celgosivir 64 entinostat 64 Sym# 64 Copegus ribavirin 64 TLK# 64 tocilizumab 64 CD3 monoclonal antibody 64 FOLFIRI 64 Solazed 64 platinum refractory 64 trastuzumab emtansine T DM1 64 OXi# 64 Folfox 64 Vicinium TM 64 Zybrestat 64 immunomodulatory therapy 64 talactoferrin 64 PSN# [002] 64 oral picoplatin 64 GLP toxicology studies 64 oral Xeloda 64 dasatinib 64 nilotinib 64 motesanib 64 including eniluracil ADH 64 AEGR 64 azacitidine 64 ON #.Na 64 eltrombopag 64 LUX Lung 64 RSD# oral 64 CD# monoclonal antibody 64 AVADO 64 Velcade bortezomib 64 eniluracil 64 cobiprostone 64 brivaracetam 64 Carfilzomib 64 pharmacokinetic equivalence 64 #I TM# 64 lenalidomide Revlimid R 64 IMC A# 64 Maximum Tolerated Dose MTD 64 hormone refractory prostate cancer 64 PI3K/Akt pathway inhibitor 64 TELINTRA 64 nalbuphine ER 64 ELOXATIN 64 Neuradiab 64 pegylated interferon alpha 64 Tyrima 64 bortezomib Velcade 64 oxymorphone ER 64 K ras mutations 64 Omacetaxine 64 solithromycin 64 orally administered inhibitor 64 histone deacetylase HDAC inhibitor 64 generation antisense inhibitor 64 figitumumab 64 xenograft models 64 PDE4 inhibitor 64 Phase Ib 64 immunomodulatory 64 OPAXIO 64 APTIVUS 64 visilizumab 64 Aurora kinase 64 adjuvant therapy 64 BCIRG 64 PROSTVAC ® 64 BiTE antibody 64 cangrelor 64 limiting toxicity 64 phase Ib 64 Zerenex 64 Pemetrexed 64 novel anticancer 64 Taxotere ® 64 hA# 64 Fibrillex TM 64 uric acid lowering 64 multiple myeloma MM 64 afatinib 64 ALA PDT 64 Dasatinib 64 CCX# B 64 HuMax CD4 64 liposomal doxorubicin 64 bevacizumab Avastin 64 OMP #M# 64 PKC# 64 SUCCEED trial 64 Tarvacin 64 Neulasta ® 64 FOLFOX chemotherapy 64 HCD# [002] 64 dose escalation Phase 64 lapatinib Tykerb 64 tezampanel 64 vicriviroc 64 ATL# [001] 64 FOLOTYN ® 64 investigational monoclonal antibody 64 Degarelix 64 recurrent GBM 64 GW# [003] 64 obatoclax 63 JAK inhibitors 63 RhuDex ® 63 deforolimus 63 TTF Therapy 63 indibulin 63 5 fluorouracil leucovorin 63 Randomized Phase 63 ofatumumab 63 Traficet EN 63 masitinib 63 estramustine 63 p# biomarker 63 Plicera 63 VNP#M 63 pralatrexate 63 trabectedin 63 follicular NHL 63 Irinotecan 63 rituximab Rituxan 63 Doxil ® 63 LymphoStat B belimumab 63 perifosine 63 dose escalation clinical 63 vismodegib 63 evaluating satraplatin 63 Epratuzumab 63 Voreloxin 63 AKT inhibitor 63 multicenter Phase II 63 rhIGFBP 3 63 dosage regimens 63 overlapping toxicities 63 GRNVAC1 63 MEK inhibitor RDEA# 63 phase Ib clinical 63 medically inoperable 63 sunitinib Sutent ® 63 Taxotere chemotherapy 63 Phase IIIb clinical 63 Bicifadine 63 Aurora kinase inhibitor 63 refractory multiple myeloma 63 systemically administered 63 BRIM3 63 FOLFOX6 63 Kahalalide F 63 sargramostim 63 MDV# 63 novel VDA molecule 63 Omnitarg 63 plasma kallikrein inhibitor 63 sPLA2 63 ZOLINZA 63 Trofex TM 63 boosted protease inhibitor 63 idarubicin 63 anti leukemic 63 ACTEMRA TM 63 metastatic renal cell 63 JAK inhibitor 63 antiangiogenic therapy 63 Amigal 63 randomized Phase III 63 Xeloda ® 63 Panzem 63 luteinizing hormone releasing 63 MyVax R 63 Interferon alpha 63 tigecycline 63 EGFR tyrosine kinase inhibitors 63 Onconase 63 ARIKACE ™ 63 genotypic resistance 63 STRIDE PD 63 dasatinib Sprycel ® 63 Temsirolimus 63 Targretin capsules 63 prostate cancer CRPC 63 GRN#L 63 cMET 63 Intravenous CP 63 Teriflunomide 63 endothelin antagonists 63 Pegasys ® 63 mCRC patients 63 phase IIb 63 canakinumab 63 ocrelizumab 63 CEQ# 63 MYDICAR ® 63 darapladib 63 XL# XL# XL# 63 idraparinux 63 fluoropyrimidine 63 GVAX 63 bovine thrombin 63 daunorubicin 63 bortezomib 63 dose cytarabine 63 Phase 1b clinical trials 63 Ophena TM 63 viral kinetic 63 XL# SAR# 63 Triapine R 63 Symadex 63 plus dexamethasone 63 AQ4N 63 herpetic keratitis 63 iclaprim 63 metastatic castrate resistant 63 Tarceva erlotinib 63 tremelimumab 63 fulvestrant 63 palifosfamide 63 BCR ABL inhibitor 63 pemetrexed 63 JAK1 63 hematological cancers 63 investigational humanized monoclonal antibody 63 castration resistant prostate cancer 63 Sudhir Agrawal D.Phil 63 SPRYCEL ® 63 volociximab 63 Chemophase 63 epigenetic therapies 63 TBC# 63 Allovectin 7 63 oral antidiabetic 63 OvaRex ® MAb 63 inhibitor RG# 63 PI3K inhibitors 63 Panzem R 63 amrubicin 63 anticancer agent 63 cetuximab Erbitux 63 adalimumab Humira 63 #D#C# 63 Phase 1b clinical 63 Erlotinib 63 epithelial tumors 63 Pertuzumab 63 Afatinib 63 Thiovir 63 LymphoStat B TM 63 KRAS mutations occur 63 samalizumab 63 humanised monoclonal antibody 63 Zevalin consolidation 63 otelixizumab 63 mg/m2 dose 63 Golimumab 63 refractory NSCLC 63 epothilone 63 Phase 1b trial 63 apremilast 63 Vectibix 63 Telatinib 63 BR.# 63 GAMMAGARD LIQUID 63 refractory AML 63 gefitinib 63 Rebif ® 63 mCRC 63 TNF blocker therapy 63 nilotinib Tasigna ® 63 R# #mg BID 63 paclitaxel carboplatin 63 Bortezomib 63 Elvitegravir 63 Dacogen injection 63 CA9 SCAN 63 GAP #B# 63 neoadjuvant chemotherapy 63 LAF# 63 T DM1 62 GALNS 62 FOLFOX 62 locoregional recurrence 62 Xeloda capecitabine 62 dexamethasone Decadron 62 CANCIDAS 62 Nexavar ® 62 chemotherapy FOLFOX 62 RGB # 62 EOquin TM 62 EndoTAG 62 Dacogen decitabine 62 refractory chronic lymphocytic 62 GFT# 62 standard chemotherapy regimens 62 Nuvion 62 BENICAR HCT 62 Torisel 62 Darinaparsin 62 cannabinor 62 investigational HCV polymerase 62 PRTX 62 interferon alfa 2b 62 evaluating T DM1 62 PEGPH# 62 abiraterone acetate 62 crizotinib PF # 62 interferon alfa 2a 62 chemotherapeutic regimen 62 Pivotal Phase III 62 APPRAISE 62 5 FU leucovorin 62 ISTODAX 62 basal bolus regimen 62 peginterferon alfa 2b 62 ACZ# 62 paclitaxel Taxol 62 MOZOBIL 62 TNF antagonist 62 lenalidomide Revlimid 62 carboplatin 62 ostarine 62 imatinib Gleevec ® 62 RDEA# 62 Troxatyl 62 HCV protease 62 pharmacodynamic profiles 62 interferon alfa 62 Aclidinium 62 TKM ApoB 62 vinca alkaloid 62 immune modulatory 62 compound AEZS 62 RG# [001] 62 ZYBRESTAT fosbretabulin 62 cisplatin vinorelbine 62 Mitoxantrone 62 panitumumab 62 panitumumab Vectibix 62 voreloxin 62 davunetide intranasal AL 62 Taxotere R 62 antibody MT# 62 ALN TTR# 62 factor Xa inhibitor 62 CIMZIA TM certolizumab pegol 62 Trofex 62 dexpramipexole 62 recurrent glioblastoma 62 antibody MAb 62 humanized anti 62 pegylated interferon alfa 2a 62 OMS# 62 QVA# 62 NEUVENGE 62 anti EGFR antibody 62 bazedoxifene conjugated estrogens 62 Tesmilifene 62 targeted radiotherapeutic 62 Pralatrexate 62 cytotoxic agents 62 mTOR inhibitor 62 EpCAM 62 darinaparsin 62 sorafenib 62 Phase 1a clinical 62 antiangiogenic activity 62 CDK inhibitor 62 pharmacokinetic interactions 62 trastuzumab Herceptin ® 62 fidaxomicin Phase 3 62 ocular formulation 62 terlipressin 62 Phase #b/#a clinical 62 refractory gout 62 myopathy rhabdomyolysis 62 mTOR inhibition 62 Solazed TM 62 tolvaptan 62 G#DT 62 Dapagliflozin 62 PEG interferon 62 taxane chemotherapy 62 satraplatin Phase 62 mitomycin 62 MGCD# [001] 62 heavily pretreated 62 NATRECOR R 62 evaluating Xcytrin 62 potent antiproliferative 62 GSK# [001] 62 chemotherapeutic drug 62 PEGylated interferon beta 1a 62 PEG PAL 62 BCX# 62 selective modulator 62 demonstrated antitumor activity 62 DAVANAT 62 Archexin 62 Tezampanel 62 optimal dosing 62 acyclovir Lauriad R 62 Ocrelizumab 62 TG# [003] 62 Pivotal Phase 62 vemurafenib 62 daclizumab 62 OvaRex R 62 hereditary deficiency 62 Gemzar ® 62 budesonide foam 62 subcutaneously administered 62 anticancer activity 62 Azedra TM 62 GPNMB 62 Phase IIb clinical trials 62 IL# PE#QQR 62 Faslodex 62 Quinamed 62 delafloxacin 62 ProSavin 62 subcutaneous PRO 62 KNS # 62 docetaxel 62 eribulin mesylate 62 nonsmall cell lung cancer 62 NEUGENE 62 Phase 2b study 62 Vectibix monotherapy 62 vinorelbine 62 ZK EPO 62 mg kg dose 62 chemoradiation therapy 62 stage IIIB 62 gemcitabine cisplatin 62 severe hypercholesterolemia 62 metastatic GIST 62 Vectibix panitumumab 62 dose escalation trial 62 lorvotuzumab mertansine 62 iroxanadine 62 NS4A 62 omega interferon 62 torezolid phosphate 62 Triapine 62 liver metastases 62 relapsed myeloma 62 Azedra ™ 62 intermittent dosing 62 SinuNase ™ 62 Trastuzumab 62 LY# [003] 62 epirubicin 62 oritavancin 62 anticancer therapy 62 comparator arm 62 Lenocta 62 NP2 Enkephalin 62 PREZISTA r 62 SCH # 62 mixed dyslipidemia 62 Ixempra 62 alfa 2a 62 Herceptin trastuzumab 62 QTc prolongation 62 neoadjuvant treatment 62 Factor VIIa 62 L MTP PE 62 Valortim R 62 generation purine nucleoside 62 anticancer compound 62 Peginterferon alfa 2b 62 oral rivaroxaban 62 Aptivus ® 62 pemetrexed Alimta 62 VEGF Trap 62 opioid induced constipation OIC 62 chlorambucil 62 non squamous NSCLC 62 elvitegravir 62 EndoTAG TM 62 Hedgehog Pathway Inhibitor 62 IMP# 62 trastuzumab 62 xanthine oxidase inhibitor 62 sodium thiosulfate STS 62 sodium glucose cotransporter 62 PD LID 62 Gleevec resistant 62 immunomodulating 62 Perifosine 62 Vidaza ® 62 serum urate 62 TPI ASM8 62 cetuximab 62 PF # [001] 62 triphendiol 62 PRECiSE 61 DU #b 61 cetuximab Erbitux ® 61 KRAS wild 61 DEB# 61 PRECISE trial 61 TEMODAL 61 alpha folate receptor 61 febuxostat 61 RhuDex TM 61 paclitaxel cisplatin 61 OncoVEX 61 Daclizumab 61 antithrombotic 61 ribavirin RBV 61 vinorelbine tartrate 61 pancreatic carcinoma 61 Clolar ® 61 interferon beta 1a 61 randomized Phase 2b 61 protein tyrosine phosphatase 1B 61 TASKi2 61 randomized controlled Phase 61 Panitumumab 61 Annamycin 61 Cleviprex TM clevidipine 61 PEGylated Fab fragment 61 monotherapy 61 histamine dihydrochloride 61 EDEMA4 61 LymphoStat B 61 recurrent malignant glioma 61 Aliskiren 61 FOLFOX4 61 Reverset 61 confirmatory clinical 61 CALGB # [001] 61 Apoptone 61 orally bioavailable 61 Erbitux cetuximab 61 XL# inhibits 61 pegfilgrastim 61 dasatinib Sprycel 61 glargine 61 invasive candidiasis 61 BrachySil TM 61 alpha 2a 61 Taxotere docetaxel 61 HER2 overexpression 61 GAMMAGARD 61 metastatic colorectal cancer 61 Proellex TM 61 TG# [001] 61 RG# ITMN 61 TNFa 61 IMiDs ® compound 61 erlotinib 61 GRNCM1 61 pharmacokinetic PK study 61 vandetanib 61 FOLPI 61 Zevalin R Ibritumomab 61 Peg IFN 61 small molecule activators 61 tarenflurbil 61 IAP inhibitor 61 chemotherapy induced neutropenia 61 oblimersen 61 subcutaneous SC 61 lixisenatide 61 Tesetaxel 61 baminercept 61 phase IIb III 61 GMX# 61 hoFH 61 canagliflozin 61 HSP# inhibitor 61 personalized immunotherapy 61 ILLUMINATE 61 Phase 1b 61 Insegia 61 IAP inhibitors 61 EGFR expressing mCRC 61 ANYARA 61 pradefovir 61 CHAMPION PCI 61 trastuzumab Herceptin 61 urocortin 2 61 peginesatide 61 L BLP# 61 doxorubicin docetaxel 61 EOquin 61 ChronVac C ® 61 MAGE A3 61 ADAGIO study 61 glatiramer 61 Phase IIb III 61 regorafenib 61 oral candidiasis 61 PEGINTRON TM 61 Ranolazine 61 danoprevir 61 dirucotide 61 ADVEXIN 61 resected pancreatic cancer 61 GnRH agonists 61 CTA# Injection 61 Genasense ® oblimersen 61 Blinatumomab 61 leading oral taxane 61 Pegasys peginterferon alfa 2a 61 Reolysin 61 Phase IIa trial 61 Phase #b/#a 61 Litx 61 MAXY G# 61 Oral NKTR 61 IV NSCLC 61 neoadjuvant therapy 61 ospemifene 61 S/GSK# 61 lexidronam injection 61 mifamurtide 61 cytotoxic chemotherapy 61 CALGB 61 advanced hepatocellular carcinoma 61 registrational 61 IIa trial 61 HQK 61 antitumor efficacy 61 motesanib diphosphate 61 Pruvel 61 zoledronate 61 polymerase inhibitor 61 AAG geldanamycin analog 61 phase IIb study 61 histone deacetylase inhibitor 61 subcutaneous formulation 61 Androxal TM 61 complete cytogenetic response 61 plasmid DNA vaccine 61 erlotinib Tarceva 61 Vidofludimus 61 Romidepsin 61 Solorel TM 61 GVAX immunotherapy 61 Neuvenge 61 drug conjugate 61 hypoxia activated prodrug 61 dose cohorts 61 tranilast 61 ruxolitinib 61 Hsp# Inhibitor 61 evaluating REVLIMID 61 bortezomib Velcade ® 61 tipranavir 61 Nexavar tablets 61 Amplimexon 61 eritoran 61 colorectal cancer liver metastases 61 chemotherapy cisplatin 61 interferon ribavirin 61 mcg dose 61 QT QTc 61 SCIg 61 PlGF 61 Hsp# inhibitors 61 Hsp# inhibitor 61 5 Fluorouracil 61 Dalbavancin 61 follicular non 61 VEGFR2 inhibitor 61 Phase 2b trial 61 Azacitidine 61 antiangiogenesis 61 A3 adenosine receptor 61 papillary renal cell carcinoma 61 anti CTLA 61 GEM OS2 61 Genasense 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 anti angiogenic agents 61 prospectively defined 61 Phase Ib clinical trials 61 allogeneic stem cell 61 Combo Stent 61 glioblastoma multiforme GBM 61 tumor lysis syndrome 61 tramiprosate Alzhemed TM 61 antidiabetic 61 beta 1a 61 OncoVex 61 Mipomersen 61 ASONEP 61 radiolabeled monoclonal antibody 61 vascular disrupting agent 61 aurora kinase 61 subgroup analyzes 61 vernakalant hydrochloride 61 rBChE 61 resminostat 61 doxorubicin cyclophosphamide 61 ZYBRESTAT 61 intravenous cyclophosphamide 61 MKC# PP 61 fluvastatin 61 myelodysplastic syndromes MDS 61 Nanobody 61 ABVD 61 receptor inhibitor 61 rALLy clinical trial 61 cutaneous T cell 61 double blinded placebo 61 Tarvacin TM 61 radiation chemoradiation 61 PROCHYMAL 61 velafermin belinostat 61 DPX Survivac